Reckitt Benckiser (RB)’s disappointing run continued unabated into Q3 17 (trading update), with the company reporting its second successive sales contraction (-1% lfl in the RB base business, Q2 17: -2%, Q3 16: +2%), albeit a tad healthier than the previous quarter’s near carnage (at -2% lfl, the worst quarter ever for the staples behemoth). The key culprit was the July 2017 cyberattack (Petya, lopping off a good c.2ppt from the top-line), with the situation getting exacerbated by
03 Dec 2017
Multiple ailments undermining RB’s Health
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Multiple ailments undermining RB’s Health
Reckitt Benckiser Group plc (RKT:LON) | 4,160 1164.9 0.7% | Mkt Cap: 29,395m
- Published:
03 Dec 2017 -
Author:
Jyoti Prakash -
Pages:
5
Reckitt Benckiser (RB)’s disappointing run continued unabated into Q3 17 (trading update), with the company reporting its second successive sales contraction (-1% lfl in the RB base business, Q2 17: -2%, Q3 16: +2%), albeit a tad healthier than the previous quarter’s near carnage (at -2% lfl, the worst quarter ever for the staples behemoth). The key culprit was the July 2017 cyberattack (Petya, lopping off a good c.2ppt from the top-line), with the situation getting exacerbated by